Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Tuesday, April 29th, 2025

MS&AD Insurance Completes ¥190 Billion Share Buyback Program in 2024








MS&AD Insurance Group Completes Significant Share Buyback

MS&AD Insurance Group Completes Significant Share Buyback

MS&AD Insurance Group Holdings, Inc. (the “Company”) has announced the completion of a noteworthy share buyback program, which could have substantial implications for shareholders and the market. The buyback was executed in accordance with Article 165, Paragraph 2 of the Companies Act of Japan and was finalized following a Board of Directors meeting held on May 20, 2024.

Key Points of the Report

  • Type of shares purchased: Common stock of the Company
  • Total number of shares purchased: 383,800 shares
  • Aggregate amount of purchase price: JPY 1,296,812,400
  • Period of purchase: November 1, 2024

Details from the Board of Directors Meeting on May 20, 2024

  • Type of shares to be purchased: Common stock of the Company
  • Total number of shares to be purchased: Up to 130,000,000 shares (8.2% of total issued shares, excluding treasury shares)
  • Aggregate amount of purchase price: Up to JPY 190,000,000,000
  • Period of purchase: From May 21, 2024, to December 23, 2024

Cumulative Purchase Details as of November 1, 2024

  • Aggregate number of shares purchased: 57,405,916 shares
  • Aggregate amount of purchase price: JPY 189,999,683,068

President & CEO Shinichiro Funabiki expressed optimism about the buyback, emphasizing its potential to enhance shareholder value. Shareholders should be aware of these developments as they could influence the Company’s stock price, given the significant amount of capital involved and the substantial percentage of shares repurchased.

Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult with a financial advisor before making investment decisions.


CSE Global Reports 15.4% Revenue Growth in Q3 2024 Despite Market Uncertainties

CSE Global Reports Strong Revenue Growth Amid Market Challenges CSE Global Reports Strong Revenue Growth Amid Market Challenges Singapore-based CSE Global Limited has announced its interim business updates for the third quarter of 2024,...

AcroMeta Group’s Bold Pivot: From Engineering to Consumer Electronics Amid Financial Challenges and Controversial Share Awards

AcroMeta Group’s Bold Diversification Sparks Shareholder Concerns AcroMeta Group’s Bold Diversification Sparks Shareholder Concerns AcroMeta Group Limited has undergone a significant transformation, shifting its business strategy and raising eyebrows among shareholders. The company’s move...

Clearbridge Health Limited Receives SGX-ST Approval for 1.28 Billion Rights Share Issuance

Clearbridge Health’s Strategic Rights Issue Receives Regulatory Green Light Clearbridge Health’s Strategic Rights Issue Receives Regulatory Green Light Clearbridge Health Limited has achieved a significant milestone as it announces the receipt of the listing...